华特达因：子公司签署褪黑素颗粒（曼乐静 ）总经销合同

Core Viewpoint - The company Huate Dain (000915) has reached an exclusive distribution agreement for melatonin granules (Manlejing) with Japan's Nobel Pharma, marking a significant development in the pediatric sleep disorder treatment market in China [1] Group 1: Company Developments - Huate Dain's subsidiary, Beijing Dain Kangjian, will serve as the exclusive distributor for the melatonin product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is set to be approved for market release in China by July 2025 [1] Group 2: Product Significance - Manlejing is the first melatonin formulation approved in China for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders [1] - This product represents the first instance of a melatonin-based substance receiving drug approval in China [1]